Cargando…
Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological res...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113307/ https://www.ncbi.nlm.nih.gov/pubmed/21575275 http://dx.doi.org/10.1186/1743-422X-8-234 |
_version_ | 1782205919639109632 |
---|---|
author | Akram, Madiha Idrees, Muhammad Zafar, Shamail Hussain, Abrar Butt, Sadia Afzal, Samia Rehman, Irshad-ur Liaqat, Ali Saleem, Sana Ali, Muhammad Butt, Azeem |
author_facet | Akram, Madiha Idrees, Muhammad Zafar, Shamail Hussain, Abrar Butt, Sadia Afzal, Samia Rehman, Irshad-ur Liaqat, Ali Saleem, Sana Ali, Muhammad Butt, Azeem |
author_sort | Akram, Madiha |
collection | PubMed |
description | BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological response than standard IFN α/ribavirin therapy. Objective of current study was to analyze rate of early and delayed response to antiviral treatment as well as rate of relapse response in patients following standard treatment IFN α/ribavirin and in patients following pegylated interferon treatment. METHODS: Baseline serum samples of 153 patients enrolled for IFN α/ribavirin and 50 patients for PegIFN/ribavirin were collected. After total RNA extraction, genotyping was and HCV RNA viral load was done. Subsequently HCV RNA viral load was estimated at 4 weeks of treatment, at 12 weeks, at 24 or 48 weeks and finally after 6 months follow up period. All the data was statistically analyzed using fisher's exact test. RESULTS: Total 86 patients out of 153 patients following conventional IFN α/ribavirin therapy completed treatment and 69% of them showed Rapid Virological Response (RVR). Whereas 50 patients following PegIFN/ribavirin treatment completed treatment and 80% of them achieved RVR. Total 64 out of 86 patients following IFN α/ribavirin therapy completed follow up period and 53.5% of them achieved Sustainded Virologcal Response (SVR). Forty-five out of total 50 patients who received PegIFN/ribavirin treatment completed 6 months follow up period and among these 70% achieved SVR. SVR rates were significantly associated with RVR (p < 0.001), age (p < 0.001) and gender (p < 0.01) CONCLUSIONS: Rate of sustained virological response can be determined by factors like rapid virological response and age since they share significant association with one another. More over rate of SVR was more prominent in males than in females. |
format | Online Article Text |
id | pubmed-3113307 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31133072011-06-14 Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients Akram, Madiha Idrees, Muhammad Zafar, Shamail Hussain, Abrar Butt, Sadia Afzal, Samia Rehman, Irshad-ur Liaqat, Ali Saleem, Sana Ali, Muhammad Butt, Azeem Virol J Research BACKGROUND: Current standard therapy commonly followed for chronic Hepatitis C Virus (HCV) in Pakistan is interferon alpha plus ribavirin combination therapy (IFN α/ribavirin) and pegylated interferon plus ribavirin (PegIFN/ribavirin). PegIFN/ribavirin has increased rate of sustained virological response than standard IFN α/ribavirin therapy. Objective of current study was to analyze rate of early and delayed response to antiviral treatment as well as rate of relapse response in patients following standard treatment IFN α/ribavirin and in patients following pegylated interferon treatment. METHODS: Baseline serum samples of 153 patients enrolled for IFN α/ribavirin and 50 patients for PegIFN/ribavirin were collected. After total RNA extraction, genotyping was and HCV RNA viral load was done. Subsequently HCV RNA viral load was estimated at 4 weeks of treatment, at 12 weeks, at 24 or 48 weeks and finally after 6 months follow up period. All the data was statistically analyzed using fisher's exact test. RESULTS: Total 86 patients out of 153 patients following conventional IFN α/ribavirin therapy completed treatment and 69% of them showed Rapid Virological Response (RVR). Whereas 50 patients following PegIFN/ribavirin treatment completed treatment and 80% of them achieved RVR. Total 64 out of 86 patients following IFN α/ribavirin therapy completed follow up period and 53.5% of them achieved Sustainded Virologcal Response (SVR). Forty-five out of total 50 patients who received PegIFN/ribavirin treatment completed 6 months follow up period and among these 70% achieved SVR. SVR rates were significantly associated with RVR (p < 0.001), age (p < 0.001) and gender (p < 0.01) CONCLUSIONS: Rate of sustained virological response can be determined by factors like rapid virological response and age since they share significant association with one another. More over rate of SVR was more prominent in males than in females. BioMed Central 2011-05-17 /pmc/articles/PMC3113307/ /pubmed/21575275 http://dx.doi.org/10.1186/1743-422X-8-234 Text en Copyright ©2011 Akram et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Akram, Madiha Idrees, Muhammad Zafar, Shamail Hussain, Abrar Butt, Sadia Afzal, Samia Rehman, Irshad-ur Liaqat, Ali Saleem, Sana Ali, Muhammad Butt, Azeem Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients |
title | Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients |
title_full | Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients |
title_fullStr | Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients |
title_full_unstemmed | Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients |
title_short | Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients |
title_sort | effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic hepatitis c patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113307/ https://www.ncbi.nlm.nih.gov/pubmed/21575275 http://dx.doi.org/10.1186/1743-422X-8-234 |
work_keys_str_mv | AT akrammadiha effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT idreesmuhammad effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT zafarshamail effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT hussainabrar effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT buttsadia effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT afzalsamia effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT rehmanirshadur effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT liaqatali effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT saleemsana effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT alimuhammad effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients AT buttazeem effectsofhostandvirusrelatedfactorsoninterferonaribavirinandpegylatedinterferonribavirintreatmentoutcomesinchronichepatitiscpatients |